Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label vortioxetine extension in pediatric major depressive disorder
2015-002658-11Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoint: Safety and tolerability of long-term vortioxetine. Started Apr 2016; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2015-002658-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002658-11.